RNS Number : 8984Q

Roquefort Therapeutics PLC

30 June 2022

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Director/PDMR Shareholding

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, advises that Stephen West, Executive Chairman has purchased ordinary shares in the Company in the market, as detailed below:

Name

Number of Ordinary Shares

Average Price Paid Per Share

Total Consideration Paid

Stephen West

289,123

8.58 pence

£24,815.91

Following the above purchase of shares, Mr West holds interests in the following Company securities:

Name

Number of Ordinary Shares Held

% of Issued Share Capital

Number of Warrants Held

Stephen West

4,839,123

6.73%

7,500,000

4,399,000 of Mr West's shares are held in the name of Cresthaven Investments Pty Ltd ATF the Bellini Trust.

Enquiries:

Roquefort Therapeutics plc
Stephen West (Chairman)	+44 (0)20 3290 9339
Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale Optiva Securities Limited (Broker)	+44 (0)20 7466 5000
Christian Dennis	+44 (0)20 3411 1881

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on Twitter.

LEI: ‎254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma. The Company is a pre-clinical biotech company focused on developing first in class Midkine targeting drugs for the treatment of cancer.

Through extensive research resulting in validation through publication in over 1,000 scientific journals, Roquefort Therapeutics has identified the potential to exploit the broad therapeutic potential of Midkine for a number of clinical indications of unmet needs. Roquefort Therapeutics holds an exclusive licence to the largest global IP portfolio on Midkine. The Midkine blocking drug development markets have significant global market potential (in the multi-billion dollars). Roquefort Therapeutic's pre-clinical program is currently underway with an initial focus on cancer.

This announcement contains inside information for the purposes of Article 7 of the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended ("UK MAR").

The notification below, made in accordance with the requirements of the UK MAR, provides further detail:

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Stephen West
2	Reason for the notification
a)	Position/status	Executive Chairman
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Roquefort Therapeutics plc
b)	LEI	254900P4SISIWOR9RH34
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of £0.01 par value ISIN: GB00BMDQ2T15
b)	Nature of the transaction	Purchase of 289,123 ordinary shares
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		8.44 pence per share 8.50 pence per share 9.00 pence per share	58,806 175,170 55,147
d	Aggregated information - Aggregated volume - Price	- 289,123 - 8.58p
e)	Date of the transactions	30 June 2022
f)	Place of the transactions	London Stock Exchange (XLON); Main Market

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBUGDLIXXDGDG